Isomorphic Labs Explores Major Funding Round

Isomorphic Labs, the artificial intelligence-driven drug discovery company spun out of Google DeepMind, is reportedly in discussions to raise approximately $5 billion in new funding. The proposed investment could value the company at around $50 billion.

The financing discussions are ongoing, and the deal has not been finalised. The reported valuation would position Isomorphic Labs among the most highly valued companies operating at the intersection of artificial intelligence and biotechnology.

Building on AI-Powered Drug Discovery

Founded in 2021, London-based Isomorphic Labs was established to apply advanced AI to the discovery and development of new medicines. Its technology builds on research from Google DeepMind, including the AlphaFold family of models, which has advanced scientific understanding of protein structures.

The company aims to use AI to improve how researchers identify potential drug candidates, understand molecular interactions and develop treatments. Its work includes collaborations with pharmaceutical companies such as Eli Lilly and Novartis, alongside its own drug development programmes.

Funding Follows a Major Previous Investment

The proposed $5 billion raise comes after Isomorphic Labs secured approximately $2.1 billion in funding in May 2026, in a round led by Thrive Capital with participation from Alphabet and other investors.

The latest discussions indicate continued investor interest in AI-powered biotechnology. However, the identities of potential investors and the final terms of the proposed funding have not been disclosed.

Clinical Progress Remains a Key Milestone

Despite significant investment and technological progress, AI-driven drug discovery still faces the challenge of translating computational research into treatments that work safely in humans.

Speaking at the Bloomberg Tech conference in London on November 2, Isomorphic Labs President Max Jaderberg said the company's drug discovery efforts remain in the preclinical stage. CEO Demis Hassabis had previously indicated that the company expected to move its first programmes into clinical trials by the end of 2026.

The proposed funding could provide additional resources for research, technology development and drug programmes. However, the company has not publicly confirmed how the reported new capital would be allocated.

What This Means for AI and Healthcare

Isomorphic Labs' reported fundraising discussions reflect growing expectations around AI's role in pharmaceutical research. While AI could help researchers explore drug candidates more efficiently, successful medicines still require extensive laboratory testing, clinical trials and regulatory approval.

If completed, the proposed funding round would represent a significant investment in the future of AI-led drug discovery. The company's progress will be closely watched as the biotechnology industry evaluates whether advanced AI systems can translate scientific predictions into effective treatments.